Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I StudyClin. Cancer Res 2022 Jan 04;[EPub Ahead of Print], J Zhang, D Ji, L Cai, H Yao, M Yan, X Wang, W Shen, Y Du, H Pang, X Lai, H Zeng, J Huang, Y Sun, X Peng, J Xu, J Yang, F Yang, T Xu, X Hu
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.